H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Kindred Biosciences (NASDAQ: KIN) today and set a price target of $16. The company’s shares opened today at $14.95, close to its 52-week high of $15.60.
Ramakanth commented:
“We maintain our Buy rating of KIN and raise our 12-month price target to $16.00 per share, up from $12.00. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate. We derive an rNPV of $395M for the pipeline products and add in $110M in cash and cash equivalents to arrive at a 12-month price target of $15.74 per diluted share, which we round to $16.00. Risks. (1) clinical and regulatory; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 7.3% and a 40.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Currently, the analyst consensus on Kindred Biosciences is a Strong Buy with an average price target of $17.33, which is a 15.9% upside from current levels. In a report issued on August 7, B.Riley FBR also reiterated a Buy rating on the stock with a $16 price target.
.
See today’s analyst top recommended stocks >>
Based on Kindred Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.24 million. In comparison, last year the company had a GAAP net loss of $6.77 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KIN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
